Population pharmacokinetics/pharmacodynamics of tigecycline in the treatment of different infectious diseases
10.12092/j.issn.1009-2501.2021.11.007
- Author:
Wenchao LI
1
;
Xiangrong BAI
1
;
Xiaoling LI
1
;
Dechun JIANG
1
;
Wenchao LI
2
Author Information
1. Department of Pharmacy, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric Disorders
2. School of Pharmacy, Capital Medical University
- Publication Type:Journal Article
- Keywords:
Atypical nonlinear plasma protein binding;
Pharmacodynamics;
Population pharmacokinetics;
Tigecycline
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2021;26(11):1265-1272
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To provide reference for the clinical application of tigecycline and subsequent population pharmacokinetic-pharmacodynamics study in the future. METHODS: The Chinese and English keywords of "Tigecycline", "population pharmacokinetics", "population pharmacokinetic model", "pharmacodynamics" or "Tigecycline" pharmacokinetics "were used to search the relevant references published from the time of self-establishment to June 1, 2021 in PubMed, China Knowledge Infrastructure, Wanfang and other databases. The research progress of population pharmacokinetics and pharmacodynamics of tigecycline was reviewed. RESULTS & CONCLUSION: A total of 73 relevant references were retrieved, including 8 tigecycline PPK studies and 7 tigecycline PK/PD studies. At present, tigecycline PPK models had been established in patients with complex intra-abdominal infections, skin and skin and soft tissue infections, community-acquired pneumonia, nosocomial pneumonia, septic shock and other severe infections, including 8 two-compartment models. The main covariates affecting tigecycline plasma clearance were weight-related, liver function and renal function-related parameters. Body weight was also an important factor influencing the apparent volume of distribution. The effect of different disease types on the pharmacokinetics of tigecycline was different, and it needed to be considered and selected in combination with the specific circumstances of patients when formulating clinical dosing regimens. Pharmacodynamics studies should consider not only the type of disease, pathogens and patient factors themselves, but also the characteristics of atypical nonlinear plasma protein binding of tigecycline. In order to accurately understand the efficacy of different dose regimens, it was necessary to monitor the therapeutic drugs of tigecycline.
